Method for tumor detection and targeted hyperthermia
The present invention provides stem cells loaded with bi-functional magnetic nanoparticles (nanoparticle-loaded stem cells (NLSC)) that both: a) heat in an alternating magnetic field (AMF); and b) provide MRI contrast enhancement for MR-guided hyperthermia. The nanoparticles in the NLSC are non-toxic, and do not alter stem cell proliferation and differentiation, the nanoparticles do however, become heated in an alternating magnetic field, enabling therapeutic applications for cancer treatment. Due to the fact that circulating stem cells home to tumors and metastasis, and participate in neovascularization of growing tumors, the NLSC of the present invention allows tracking of the tissue distribution of infused stem cells and selective heating of targeted tissues with AMF. NLSC can deliver hyperthermia to hypoxic areas in tumors for sensitization of those areas to subsequent treatment, thus delivering therapy to the most treatment-resistant tumor regions. The heating of diseased tissue either results in direct cell killing or makes the tumor more susceptible to radio- and/or chemotherapy. The targeted hyperthermia provided by the present invention has clinical potential because it is associated with fewer side effects, and can also be used in combination with conventional treatment modalities, significantly enhancing their effectiveness. The NLSC of the present invention can be used for MR image-guided hyperthermia in oncology, in stem cell research for cell tracking and heating, and for elimination of mis-injected stem cells.
1. A method for treating a tumor in a subject, comprising:
a) administering intravenously to the subject an amount of mesenchymal stem cells loaded with bi-functional nanoferrite magnetic nanoparticles;
b) allowing sufficient time for the mesenchymal stem cells loaded with the bi-functional nanoferrite magnetic nanoparticles to localize to the tumor; and,
c) applying an alternating magnetic field to the subject and heating the bi-functional nanoferrite magnetic nanoparticles loaded into the mesenchymal stem cells localized to the tumor, thereby heating the tumor in the subject.
2. The method of claim 1 , wherein the bi-functional nanoferrite magnetic nanoparticles comprise a core of 75-80% (w/w) magnetite.
3. The method of claim 1 , wherein the mesenchymal stem cells comprise stem cells selected from the group consisting of autologous stem cells and allogenic stem cells.
4. The method of claim 3 , wherein the autologous stem cells are selected from the group consisting of: a) cells derived from circulation or endothelial progenitor cells; b) cells derived from bone marrow; and c) cells obtained from cell banks.
5. The method of claim 3 , wherein the allogenic stem cells are selected from the group consisting of: a) cells derived from non-embryonic tissues or adult stem cells; and b) cells derived from human embryonic stem cell (hESC) lines from in vitro fertilization (IVF) embryos.
6. The method of claim 1 , further comprising: detecting the tumor by imaging the mesenchymal stem cells loaded with the bi-functional nanoferrite magnetic nanoparticles localized at the tumor through magnetic resonance imaging (MRI) before step c).
7. The method of claim 1 , wherein the amount of mesenchymal stem cells is between 1×10 3 to 1×10 11 cells.
8. The method of claim 1 , wherein the sufficient time for the mesenchymal stem cells to localize to the tumor is between 3 days to 10 days.
9. The method of claim 1 , wherein the magnetic field strength of the alternating magnetic field administered to the subject is between 500 Gauss to 1500 Gauss.
10. The method of claim 9 , wherein the magnetic field amplitude of the alternating magnetic field is between 5 Oe to 1000 Oe.
11. The method of claim 1 , wherein the tumor is a solid tumor.
12. The method of claim 1 , wherein the tumor is a primary tumor.
13. The method of claim 1 , wherein the tumor is a metastatic tumor.
14. The method of claim 1 , further comprising: administering a pharmaceutical composition comprising one or more chemotherapeutic agents before or after the mesenchymal stem cells loaded with the bi-functional nanoferrite magnetic nanoparticles are localized at the tumor.
15. The method of claim 14 , further comprising: administering an effective amount of radiotherapy to the tumor.
16. The method of claim 1 , further comprising: administering an effective amount of radiotherapy to the tumor.
17. The method of claim 1 , further comprising: detecting the tumor by imaging the mesenchymal stem cells loaded with the bi-functional nanoferrite magnetic nanoparticles localized at the tumor through magnetic resonance imaging (MRI) before step c).